Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1694161

registered interest
date	06/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 February 2024 to Question 15459 on Diabetes: Medical Equipment, what the evidential basis is for growth in the prescribing of diabetes technology for people living with type 2 diabetes.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	17412
answer	answer is ministerial correction date of answer 13/03/2024 answer text <p>The National Institute for Care and Excellence (NICE) published a recommendation in March 2023 that people with type 2 diabetes, who have multiple daily insulin injections and a condition or disability that means they cannot use capillary blood glucose monitoring, should be offered Continuous Glucose Monitoring (CGM) technology, either real time or intermittent, to support self-monitoring.</p><p> </p><p>The NICE also recommended in March 2023 that adults with insulin-treated type 2 diabetes having their blood glucose monitored by a care worker or healthcare professional, are offered CGM. The rationale is that CGM can help to improve glycaemic control in adults with type 2 diabetes who use insulin.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/03/2024 16:04:37 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4488 label Biography information for Martyn Day

431985

registered interest
date	24/11/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Meningitis: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what forecast his Department has made of (a) the reduction in cases of and deaths from infection with meningococcal disease caused by groups A, C, W, and Y as a result of the introduction of the Men ACWY vaccine in 2015, (b) the number of Men ACWY vaccines which will be administered and (c) the cost of delivering that programme in each year of its operation.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	17412
answer	answer is ministerial correction date of answer 02/12/2015 answer text <br /><p>The MenACWY programme was introduced in August 2015 as an emergency programme to control a national outbreak of meningococcal group W (MenW) disease.</p><br /><p>From August 2015 to the end of August 2017 the MenACWY programme will offer a single dose of vaccine to individuals born between 1 September 1996 and 31 August 2003 inclusive. In addition, vaccines will be offered to those entering university for the first time aged up to 25 years (excluding individuals in the previously mentioned birth cohort). The number of doses given will depend on uptake, i.e. the proportion of eligible individuals who receive the vaccine.</p><br /><p>Due to the emergency status and aims of this programme, a formal cost-effectiveness analysis was not performed, part of which would have been an estimation of the reduction in cases and deaths from invasive meningococcal disease (IMD). The MenACWY vaccine is currently replacing the MenC vaccine used in the existing adolescent and university freshers’ programmes.</p><br /><p>The forecast cost of delivering the MenACWY programme in each year.</p><table><tbody><tr><td><p>Year</p></td><td><p>Estimated cost of delivering the MenACWY programme</p></td></tr><tr><td><p>2015/16</p></td><td><p>£35 million</p></td></tr><tr><td><p>2016/17</p></td><td><p>£30 million</p></td></tr><tr><td><p>2017/18</p></td><td><p>£20 million</p></td></tr></tbody></table><br /><p><em>Note:</em> These are the full programme costs (including cost of the vaccine) for England, inclusive of VAT.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 02/12/2015 17:49:13 answering member 3918 label Biography information for Jane Ellison
tabling member	1506 label Biography information for Andrew Gwynne